Literature DB >> 23035981

Promoter-associated small double-stranded RNA interacts with heterogeneous nuclear ribonucleoprotein A2/B1 to induce transcriptional activation.

Jia Hu1, Zhong Chen, Ding Xia, Jia Wu, Hua Xu, Zhang-Qun Ye.   

Abstract

Several recent reports have demonstrated that small activating dsRNA [double-stranded RNA; saRNA (small activating dsRNA)] complementary to promoter regions can up-regulate gene expression in mammalian cells, a phenomenon termed RNAa (RNA activation). However, the mechanism of RNAa remains obscure with regard to what is the target molecule for promoter-targeted saRNA and what are the proteins involved in this process. p21Waf1/Cip1 (p21) [CDKN1A (cyclin-dependent kinase inhibitor 1A)], an important tumour suppressor gene, is among the genes that can be activated by RNAa in tumour cells. In the present study, we provide direct evidence that p21 promoter-targeted saRNA interact with its intended target on the p21 promoter to activate p21 expression. This process is associated with recruitment of RNA polymerase II and AGO2 (argonaute 2) protein to the saRNA-target site. Additionally, we found that several hnRNPs (heterogeneous nuclear ribonucleoproteins) (A1, A2/B1 and C1/C2) are associated with saRNA. Further studies show that hnRNPA2/B1 interacts with the saRNA in vivo and in vitro and is required for RNAa activity. These findings indicate that RNAa results from specific targeting of promoters and reveals additional mechanistic details of RNAa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23035981     DOI: 10.1042/BJ20120256

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Upregulation of RECK gene expression by small double-stranded RNA targeting the promoter region.

Authors:  F Sakurai; Y Nanjo; S Okamoto; M Tachibana; H Mizuguchi
Journal:  Cancer Gene Ther       Date:  2014-03-21       Impact factor: 5.987

Review 2.  RNA-mediated gene activation.

Authors:  Alan L Jiao; Frank J Slack
Journal:  Epigenetics       Date:  2013-11-01       Impact factor: 4.528

3.  Oligonucleotide therapies for disorders of the nervous system.

Authors:  Olga Khorkova; Claes Wahlestedt
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

4.  Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy.

Authors:  W Xia; D Li; G Wang; J Ni; J Zhuang; M Ha; J Wang; Y Ye
Journal:  Cancer Gene Ther       Date:  2016-09-09       Impact factor: 5.987

5.  miRNA activation is an endogenous gene expression pathway.

Authors:  Luis M Vaschetto
Journal:  RNA Biol       Date:  2018-04-03       Impact factor: 4.652

Review 6.  Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism.

Authors:  Yo-Ichi Ishida; Masahiko Takeshita; Hiroaki Kataoka
Journal:  World J Hepatol       Date:  2014-12-27

7.  RNA Activation of the Vascular Endothelial Growth Factor Gene (VEGF) Promoter by Double-Stranded RNA and Hypoxia: Role of Noncoding VEGF Promoter Transcripts.

Authors:  Pascal Lopez; Kay-Dietrich Wagner; Paul Hofman; Emmanuel Van Obberghen
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

8.  A nuclear perspective on RNAi pathways in metazoans.

Authors:  Germano Cecere; Alla Grishok
Journal:  Biochim Biophys Acta       Date:  2013-12-17

9.  Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.

Authors:  Vikash Reebye; Pål Sætrom; Paul J Mintz; Kai-Wen Huang; Piotr Swiderski; Ling Peng; Cheng Liu; Xiaoxuan Liu; Steen Lindkaer-Jensen; Dimitris Zacharoulis; Nikolaos Kostomitsopoulos; Noriyuki Kasahara; Joanna P Nicholls; Long R Jiao; Madhava Pai; Duncan R Spalding; Malkhaz Mizandari; Tinatin Chikovani; Mohamed M Emara; Abdelali Haoudi; Donald A Tomalia; John J Rossi; Nagy A Habib
Journal:  Hepatology       Date:  2013-12-09       Impact factor: 17.425

Review 10.  RNA-based therapeutics for colorectal cancer: Updates and future directions.

Authors:  Jingwen Liu; Bin Guo
Journal:  Pharmacol Res       Date:  2019-12-19       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.